Trial Profile
Real world treatment patterns and outcomes for young women with HR+/HER2- metastatic breast cancer in the United States.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jan 2018
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Fulvestrant; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Jan 2018 New trial record
- 09 Dec 2017 Results assessing treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States presented at the 40th Annual San Antonio Breast Cancer Symposium